Sutro Biopharma STRO 深 沪
等待开盘 10-09 09:30:00 美东时间
15.32
+0.660
+4.50%
华盛通- 最 高16.205
- 今 开14.46
- 成交量 50.00万股
- 最 低 14.40
- 昨 收 14.66
- 总市值 2.54亿
- 52周最高 43.85
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 7.211
- 委 比 -15.25%
- 总股本 1658.12万
- 历史最高 283.00
- 量 比 2.22
- 振 幅 12.31%
- 历史最低 5.231
- 每 手 1
- 风险率 8.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
Vaxcyte, Inc. announced the pricing of concurrent public offerings totaling approximately $1 billion, including shares of common stock, pre-funded warrants, and convertible senior notes. The company plans to use the proceeds for clinical development of its VAX-31 and VAX-24 vaccine candidates, manufacturing scale-up, commercial preparations, and other research and development activities. The offerings are expected to close on October 9, 2026, sub...
10-07 02:48
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
Sutro Biopharma appointed Lucas Donigian as Senior Vice President, Business Development, leveraging his 20+ years of biotech experience, including over $2B in oncology partnerships. Donigian will help advance Sutro’s ADC platform and pipeline, including STRO-004, STRO-006, and STRO-227, while building strategic collaborations. He previously led business development at Zymeworks and NanoString Technologies. Sutro granted Donigian stock options and...
09-29 12:00
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
Vaxcyte appoints Luis Jodar, Ph.D., as Chief Medical Officer and David McAvoy, J.D., as Chief Legal Officer. Jodar brings over 30 years of experience in vaccine development, including leadership at Pfizer, while McAvoy has three decades of legal leadership in the biopharmaceutical industry. The company also updated its timeline for topline data from the VAX-31 adult Phase 3 OPUS-1 trial, now expected by the end of October 2026.
09-03 20:05
Vaxcyte to Participate in Upcoming Investor Conferences
Vaxcyte, Inc. announced that its management will participate in fireside chats and host one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference (September 8-10, 2026) and the Cantor Global Healthcare Conference (September 9-11, 2026). The fireside chats will be webcast live and available for 30 days post-conference. Vaxcyte is a vaccine innovation company developing high-fidelity vaccines, including VAX-31 and VAX-24, which aim t...
08-27 20:05
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target
Wedbush analyst David Nierengarten reiterates Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $60 price target.
08-13 20:54
Why is Sutro Biopharma Stock Falling On Wednesday?
Sutro Biopharma, Inc. (NASDAQ:STRO) shares are trading lower on Wednesday as the company faces challenges following its recent update on the STRO-004 Phase 1 study. The STRIVE-01 study is evaluating STRO-004 in heavily pretreated patients with advanced solid tumors. What’s Driving Sutro Biopharma (S...
08-13 02:04
Sutro Biopharma shares are trading lower after the company reported worse-than-expected Q2 financial results.
Sutro Biopharma shares are trading lower after the company reported worse-than-expected Q2 financial results.
08-12 22:19
Sutro Biopharma Q2 Results Highlight Advancing ADC Pipeline
An announcement from Sutro Biopharma ( ($STRO) ) is now available. On August 12...
08-12 19:48
Sutro Biopharma Q2 EPS $(2.33) Misses $(2.19) Estimate, Sales $9.839M Miss $13.048M Estimate
Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(2.33) per share which missed the analyst consensus estimate of $(2.19) by 6.39 percent. This is a 66.43 percent decrease over losses of $(1.40) per share from the same period last year. The company reported quarterly sales of $9.839 millio...
08-12 19:02
